Monoclonal antibodies targeting the immune checkpoint molecule PD1 can interrupt the PD1/PD‐L1/PD‐L2 signal on effector immune cells, such as CD8+ T cells, leading to anti‐tumour activity.5 This evidence concerns the gene CD8A and neoplasm.